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Abstract
We consider the problem of functional matrix factorization, finding
low-dimensional structure in a matrix where every entry is a noisy function
evaluated at a set of discrete points. Such problems arise frequently in
drug discovery, where biological samples form the rows, candidate drugs
form the columns, and entries contain the dose-response curve of a sample
treated at different concentrations of a drug. We propose Bayesian Tensor
Filtering (BTF), a hierarchical Bayesian model of matrices of functions.
BTF captures the smoothness in each individual function while also being
locally adaptive to sharp discontinuities. The BTF model is agnostic to
the likelihood of the underlying observations, making it flexible enough to
handle many different kinds of data. We derive efficient Gibbs samplers
for three classes of likelihoods: (i) Gaussian, for which updates are fully
conjugate; (ii) Binomial and related likelihoods, for which updates are
conditionally conjugate through Pólya–Gamma augmentation; and (iii)
Black-box likelihoods, for which updates are non-conjugate but admit an
analytic truncated elliptical slice sampling routine. We compare BTF
against a state-of-the-art method for dynamic Poisson matrix factorization,
showing BTF better reconstructs held out data in synthetic experiments.
Finally, we build a dose-response model around BTF and show on real
data from a multi-sample, multi-drug cancer study that BTF outperforms
the current standard approach in biology. Code for BTF is available at
https://github.com/tansey/functionalmf.
1 Introduction
To search for new therapeutics, biologists carry out exploratory studies of drugs.
They test multiple drugs, at different doses, against multiple biological samples
∗wesley.tansey@columbia.edu (corresponding author)
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Figure 1: Sample of data from a simulated cancer drug experiment with
correlated errors and heteroskedastic observation noise. Bands represent 50%
posterior predictive credible intervals for observations.
(e.g., different tumors). The goal is to trace the dose-response curves, and to
understand the efficacy of each drug.
The experiments in such dose-response studies are costly; each one can take
weeks or months to conduct in the lab. Consequently, a good predictive model
of dose-response is useful as a tool for interactive experimental design. With a
predictive model, biologists can prioritize some experiments over others based
on its predictions and its levels uncertainty around them.
Figure 1 shows a simulated study about cancer drug discovery.1 Each panel
illustrates the interaction of one type of drug with one type of tumor. The black
line illustrates the true dose-response curve for that drug and that tumor, and
the gray points simulate a set of experiments, each set with 6 replicates measured
at 9 different doses. The goal is to use the observations (gray points) to predict
the true dose-response curves (black lines). In Figure 1, those predictions—the
orange lines and uncertainty bands—come from Bayesian tensor filtering (BTF),
the method we propose in this paper.
Notice there is relational structure in the outcomes: each drug has similar
effects on both tumors. Thus, we treat predictive modeling of dose-response
as a factorization problem. The relational structure in the data arises because
tumors share latent molecular attributes, such as genomic mutations, and drugs
share latent pharmaceutical attributes, such as chemical structures. In each
experiment, tumor and drug attributes interact, creating the shared patterns of
dose-response.
While traditional factorization considers a matrix of scalars, the entries of
1Privacy concerns prevent us from plotting real data; we analyze a real dataset in Section 5.
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this matrix are latent dose-response curves subsampled at different doses. To
model such curves, we model drug attributes as changing functions of dose.
Moreover, while the effects usually vary smoothly, there are occasional sharp
jumps, such as between the fifth and sixth dose levels of drug 2. Capturing latent
structure in dose-response curves requires handling this type of non-stationarity.
As a final wrinkle, depending on the drugs being tested, equipment being
used, or samples under study, the types of observations will change. Some studies
may generate count data for the number of cells surviving; others measure a
real-valued metric of cell health or survival. In the case of cancer, drugs are
chosen that will only kill cells, not facilitate growth; effects in these curves are
therefore upper bounded. All of these complexities mean that good models
of dose-response curves must handle many different likelihoods and allow the
scientist to encode biological constraints on parameter values.
Bayesian tensor filtering (BTF) is a probabilistic method for functional matrix
factorization that handles these special properties of data about dose-response
curves. BTF uses structured shrinkage priors that encourage smoothness in the
estimated functions; it is locally adaptive, enabling the functions to make sharp
jumps when the data calls for it; and it can accommodate any likelihood function.
We derive efficient MCMC inference methods for BTF: specialized inference
for the Gaussian and binomial likelihoods, and a new inference method called
generalized analytic slice sampling (GASS), for more general likelihoods. BTF
enables us to develop a new state-of-the-art method for dose-response modeling
in cancer drug studies.
Contributions. This paper makes the following contributions: (i) Bayesian
tensor filtering, a flexible model for functional matrix factorization (Section 2); (ii)
generalized analytic slice sampling, a procedure for sampling from posteriors with
constrained multivariate normal priors and non-conjugate likelihoods (Section 3);
and (iii) a new Bayesian dose-response model for multi-drug, multi-sample cancer
studies, built on top of BTF and GASS (Section 4). In Section 5 we empirically
study BTF. We compare it to a state-of-the-art method for functional Poisson
matrix factorization and find it better models non-stationary functional matrices.
We also study the dose-response model on a real cancer dataset and find it
has better reconstruction performance than standard approaches used in the
dose-response literature.
Related work. We survey a collection of the most relative work to the
BTF model. Much more work has been done on many of the components in
BTF. We refer the reader to Bhadra et al. [2] for a more complete survey on
horseshoe shrinkage in complex models. For an overview of trend filtering, see
Tibshirani [23]; see Faulkner and Minin [7] for a Bayesian extension.
Bayesian factor modeling. Many models have been developed for Bayesian
factor analysis with smooth structure. Zhang and Paisley [28] apply a group
lasso penalty to the rows and columns of a matrix then derive a variational
EM algorithm for inference. Hahn et al. [10] use horseshoe priors for sparse
Bayesian factor analysis in causal inference scenarios with many instrumental
variables. Kowal et al. [12] develop a time series factor model using a Bayesian
trend filtering prior on top of a linear dynamical system with Pólya–Gamma aug-
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mentation for binomial observations. Schein et al. [18] develop poisson-gamma
dynamical systems (PGDS), a dynamic matrix factorization model specifically
for poisson-distributed observations; we compare BTF with a tensor extension of
PGDS in Section 5. Unlike the above models, BTF is likelihood-agnostic through
GASS inference and enables modeling of independently-evolving columns rather
than a common time dimension.
Dose-response modeling. Inferring the effects of a drug on biological samples
is a common task in biology. The state of the art is a logistic factor model [25]. In
large-scale studies [e.g., 8], hundreds of thousands of experiments are conducted
automatically via robots over a series of years. When such massive datasets
are available, deep learning methods have been shown to improve dose-response
modeling [22]. The focus of the BTF dose-response model is on pilot studies con-
ducted in the lab by scientists, where often the techniques being used are too new
to be scaled up via robots or the samples being experimented on require expert
preparation that cannot be automated. This is the case, for instance, in many
oragnoid experiments [5]; our case study in Section 5 is on an organoid dataset.
2 Bayesian tensor filtering for functional matrix
factorization
Let Y ∈ RN×M×T×R be an N × M matrix of noisy functions evaluated at
T points, with each point observed R times. The goal in functional matrix
factorization is to leverage the relational structure between entries to denoise the
observations and predict missing functions. We develop Bayesian tensor filtering
(BTF), a hierarchical model of functional matrices. Since our main application
is dose-response modeling, we describe BTF in terms of Y being a matrix of N
biological samples tested against M drugs, each at T doses with R replicates.
Latent attributes for biological samples. Biological samples in a study will
share molecular attributes. In cancer, different tumor samples will contain similar
patterns of genomic mutations, copy number alterations, and gene expression
[26]. In mixed tissue experiments, cells that have differentiated into the same
type will often respond similarly [e.g., 11]. These attributes are captured in
BTF with a latent vector, wi ∈ RD for the ith sample, as in standard matrix
factorization,
wi ∼ MVN(0, σ2I) , σ−2 ∼ Gamma(0.1, 0.1) . (1)
The choice of the embedding size, D, is a hyperparameter.
Latent dose-specific attributes for drugs. For the jth column in the func-
tional matrix, BTF models an entire curve Vj ∈ RT×D. Intuitively, we expect
the effects to mostly vary smoothly with dose. In BTF, this translates to the
prior belief that Vjt and Vj(t+1) should be similar. To encode this, we place
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priors on the differences between dose-specific drug embeddings, rather than on
the embeddings themselves,
(∆(k)Vj)` ∼ MVN(0, ρ2τ2j`I) . (2)
We call ∆(k) ∈ RL×T the composite trend filtering matrix; it contains all (0, . . . , k)
trend filtering [23] matrices. The ordinary trend filtering matrix encodes only
the (k+ 1)th-order differences, implicitly assuming all lower-order differences are
not smooth. The composite trend filtering matrix encodes all (q + 1)th-order
differences for q = 1, . . . , k. For example, the k = 1 case yields a prior on the
first and second order differences,
∆(1) =

1 0 0 0 . . . 0 0 0
1 −1 0 0 . . . 0 0 0
0 1 −1 0 . . . 0 0 0
. . .
0 0 0 0 . . . 0 1 −1
1 −2 1 0 . . . 0 0 0
0 1 −2 1 . . . 0 0 0
. . .
0 0 0 0 . . . 1 −2 1

. (3)
The first line of eq. (3) places an independent prior on the first dose level in each
drug, vj1, to make the matrix non-singular and to ensure the prior is proper [21].
Column independence distinguishes functional matrix factorization from
time-series tensor factorization [27, 19, 9, 20] where all columns are progressing
through time together. In BTF, columns are evolving independently, though
potentially with similar latent attributes. This independent evolution captures
the notion that two drugs treated at the same concentration may have totally
different effects due to the molecular size of the drug, its targeting receptor, and
its chemical structure.
Global-local shrinkage priors. The variance parameters in eq. (2) control
the smoothness of each curve. Small values of ρ2 and τ2j` will shrink the (j, `)
th
difference to nearly zero, resulting in the curve being smoother; larger values
enable the curve to jump in response to the data. BTF uses a global-local
shrinkage model [16] where ρ2 controls the smoothness of the entire matrix and
τ2j` is a local shrinkage term for a specific drug at a specific dose. BTF places a
horseshoe+ (HS+) prior [3, 1] on the shrinkage parameters,
τj` ∼ C+(0, φj`) φj` ∼ C+(0, 1) ρ ∼ P (ρ) . (4)
The HS+ prior is asymptotic at zero and consequently shrinks most τj` values to
nearly zero. However, it has heavy tails that decay very slowly. Thus, when the
data suggests that a change in dose results in a sharp change in effect, the drug
attributes are able to make sharp jumps. As noted by Bhadra et al. [1], a full
Bayesian specification could choose a reasonable prior for ρ, such as a standard
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Cauchy or Uniform(0, 1). If an estimate of the number of non-zero entries is
available, Van Der Pas et al. [24] make an asymptotic argument for setting ρˆ
to the expected number of non-zeros. In practice, we find BTF is robust to the
choice of global shrinkage parameter and instead perform a grid search over a
handful of ρ values.
Posterior inference. Inference in BTF is performed through an efficient
Gibbs sampler. The updates for the latent attributes depend on the form of
P (yijt;w
>
i vjt), the likelihood function for sample i, treated with drug j, at dose
t. Specifically, likelihoods fall into three categories: (i) Gaussian, for which
updates are fully conjugate; (ii) binomial and related likelihoods, for which
updates are conditionally conjugate through Pólya–Gamma augmentation; and
(iii) black-box likelihoods, for which updates are non-conjugate. The derivations
for the Gaussian and binomial categories are in appendices A and B, respectively;
the horseshoe parameter updates are in appendix C. In the remainder of the
paper, we focus on inference for non-conjugate likelihoods, as this is the category
of observations for the Bayesian dose-response model in Section 4.
3 Generalized analytic slice sampling for black-
box likelihoods
Posterior inference in BTF is done via Gibbs sampling. However, this requires us
to be able sample from the conditional distributions for each of our parameters.
For generic likelihoods, the conditional distributions of the latent attributes
wi and vjt are typically not available in closed form. Moreover, the likelihood
may impose hard constraints on the values of matrix entries. For instance, in
Poisson factorization, the w>i vjt corresponds to the Poisson rate of observed
entries in the tensor, which must always be positive. In other cases, such as
the dose-response model in Section 4, the inner product may parameterize a
probability or percentile, requiring w>i vjt ∈ [0, 1]. A naive MCMC-within-Gibbs
step with rejection sampling for invalid proposals will have a high rejection rate
and lead to poor mixing. In this section, we present an exact approach for
generic likelihoods that handles arbitrary linear constraints.
Sampling from the conditional distributions of the latent attributes can be
reduced to the problem of sampling from the posterior of a vector x with a
multivariate normal prior constrained by a set of linear inequalities,
x ∼ P (y;x)MVN(x;µ,Σ)I[Dx ≥ γ] . (5)
Slice sampling [15] samples from P (x|y) by sampling over the augmented joint
distribution P (x,  | y) where  = P (y | x). When the prior is an unconstrained
multivariate normal, the augmentation can be done by noting that a multivariate
normal forms an ellipse of equal probability. Elliptical slice sampling [14]
samples from the posterior on x by sampling a candidate ellipse v from the
prior and sampling an angle θ ∈ [−pi, pi] such that x′ = xcos(θ) + vsin(θ) and
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Algorithm 1: Generalized analytic slice sampling (GASS) for constrained
MVN priors
Data: Valid current point x, mean µ, covariance Σ, log-likelihood L,
constraints (D, γ)
Result: MCMC sample from P (x′) ∝ exp(L(x′))MVN(x′;µ,Σ)I[Dx′ ≥ γ]
t = L(x) + log ,  ∼ U(0, 1);
Sample proposal v ∼ MVN(v;0,Σ);
Grid approximation G = grid(−pi, pi);
foreach constraint (di, γi) ∈ (D, γ) do
a = d>i (x− µ), b = d>i v, c = γi − d>i µ;
if a2 + b2 − c2 ≥ 0 and a 6= −c then
Get θ1, θ2 as in eq. (6);
if a2 > c2 then
G = G⋂[θ1, θ2];
else
G = G⋂([−pi, θ1]⋃[θ2, pi]);
end
end
end
Generate candidate samples X = {x′ : xcos(θg) + vsin(θg) + µ, θg ∈ G};
Select uniformly from sufficiently likely candidates {x′ : L(x′) ≥ t, x′ ∈ X}.
P (y;x′) ≥ P (y;x) × u , u ∼ U(0, 1). Adding constraints as in eq. (5) could be
handled by pushing the constraints into the likelihood, but would result in high
rejection rates.
We extend elliptical slice sampling to directly handle constrained multivariate
normal priors. Our approach is a generalization of the analytic slice sampling
procedure of Fagan et al. [6] for truncated multivariate normals. The key
difference is that the original analytic slice sampler only considered centered
truncated multivariate normals with no likelihood component. Generalizing this
procedure to handle the more general case in eq. (5) introduces several edge
cases.
Algorithm. The full GASS procedure is procedure is presented in Algorithm 1.
Briefly, the idea of GASS is to note that the constraints can be pushed inside
the proposal update. Given a single constraint requiring that our output point
satisfies d>x′ ≥ γ, a valid angle θ must satisfy acosθ + bsinθ − c ≥ 0, where
a = d>(x − µ), b = d>(v − µ), and c = γ − d>µ. Basic trigonometry implies
that the feasible range of θ is a subset of [−pi, pi] whose boundary points are
θ1, θ2 = 2arctan
(
b±√a2 + b2 − c2
a+ c
)
. (6)
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Two cases cause the entire ellipse to be valid: (i) (a2 + b2 − c2) < 0 and (ii)
a = −c. In the first case, a2 + b2 < c2 ⇒ acosθ + bsinθ > c, for all θ. In the
second case, the only place the constraint touches the ellipse is on the extremal
point of the ellipse and thus its selection has probability zero. For all other cases,
the subset is determined based on the sign of a2 − c2. A positive sign indicates
the quadratic in the inequality is concave and eq. (6) defines the boundaries of a
contiguous region; a negative sign indicates convexity and thus the complement
of the interval. As our output sample may need to satisfy many such constraints,
we can simply repeat the above process to find all the valid regions and take
their intersection. We then numerically approximate the valid θ regions with
a fine-grained 1D grid. Sampling is performed in a quasi-Monte Carlo fashion,
uniformly over the valid grid points.
Conditioning heuristic. Elliptical slice sampling schemes like GASS can
suffer from poor mixing when the likelihood overwhelms the prior. In this case,
the angle of the ellipse will be very sharp, causing the sampler to have a small
region of the posterior that it can jump to with non-negligible probability at
each step. Fagan et al. [6] suggest using an expectation propagation for generic
truncated normals. In the case of BTF, the prior parameters forW are a function
of V , and vice versa. Thus, expectation propagation would need to be performed
every iteration of the Gibbs sampler, which would considerably increase the
computational cost of inference.
We instead approximate the entire functional matrix once at the start, by
a constrained matrix factorization. This is fast as it only requires alternating
between solving linear programs for the rows and columns. After fitting the
rows and columns, we calculate an over-estimate of the variance, analogous to an
EP approximation, as a multiple of the empirical squared error in the estimate
for each column and row. BTF uses the pseudo-EP approximation at every
step in the Gibbs sampler to calculate an adjusted prior, following the same
updates as in the Gaussian likelihood case (see appendix A for details). The
log-likelihood used in the GASS procedure is then the original log-likelihood
minus the log-pseudo-EP likelihood, leaving the resulting distribution equivalent
but increasing the range of admissible angles θ.
4 Bayesian dose-response modeling for cancer drug
discovery studies
The BTF model is a general framework for functional matrix factorization. To
apply this framework to dose-response data requires an extra set of modeling
steps on top of BTF. Here we describe the drug experiments in detail and an
empirical Bayes procedure to estimate the observation likelihood in the face of
technical error.
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Figure 2: Left: The layout of each microwell plate experiment used to generate
a single functional matrix entry. Cells are pipetted one column at a time, leading
to correlated errors. Right: Estimate of the prior distribution of mean cell counts
in each column, relative to the control column mean. The prior is estimated
empirically assuming the lowest concentration had no effect if it had a higher
mean.
Experimental design and technical error. Each functional matrix entry
is derived from a microwell plate experiment where a one drug is tested against
a one biological sample. Each experiment measures cell counts after applying
the drug at 9 different concentrations. The cell counts are measured relative
to a baseline control population where no drug was applied. For the control
and each concentration level, 6 replicates are tested. Figure 2a shows the design
of each 60-well plate experiment. All experiments are normalized by dividing
the population size estimates at each concentration by the control mean for the
plate.
The first step in each experiment is to pipette an initial population of cells
into each of the 60 microwells on the plate. This is a time consuming process
for the biologist, often taking hours to pipette a single plate. To speed up
the plating process, biologists use a multi-headed pipette that enables them to
simultaneously fill an entire column of each plate. This reduces the burden on
the biologist, but comes at a cost: correlated errors.
When a biologist fills a microwell, they first draw a pool of cells into the
pipette. Given the small volumes involved in laboratory experiments, the actual
number of cells drawn can vary substantially on a relative basis. Using a multi-
headed pipette transforms this variation into a hierarchical model: first a pool of
cells is drawn into the pipette, then it is split among all the heads. The majority
of the variation comes in the initial sampling, with small noise added in the
splitting process. This has the unintended side effect of creating correlated errors
between all microwells in a single column.
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Empirical Bayes likelihood estimation. The correlated errors in the columns
render the exact effects unidentifiable. Each column has two latent variables
affecting the final population size of cells: a dose-level effect from the drug and an
initial population size from the pipetting. Since both of these variables affect all
replicates in a column, disentangling them precisely is impossible. Nevertheless,
an estimate of dose-response must be provided.
We take an empirical Bayes approach to disentangling the variation in
drug effects from the technical error in pipetting. In most experiments, the
lowest concentration tested is too small to have any effect on cell survival. We
therefore make the assumption that any experiment where the mean of the
control replicates is lower than the mean of the replicates treated at the lowest
concentration has effectively two sets of control columns. This enables estimation
the variation between means and form an empirical Bayes prior for the pipetting
error.
Specifically, we form a histogram of all lowest-concentration means greater
than the control mean on the same plate. We then fit a Poisson GLM with 3
degrees of freedom to the histogram to estimate the prior probability that the
mean of the initial population of cells was higher than the control mean. We
then assume the true distribution is symmetric and obtain our empirical Bayes
prior on the means. Figure 2b shows an example histogram and empirical Bayes
prior estimate. The within-column variance is identifiable and estimated using
the controls. The empirical Bayes likelihood is then a gamma mixture model
that integrates out our uncertainty in the initial population mean,
P (yijt | w>i vjt) =
K∑
k=1
(
R∏
r=1
mˆkGa(yijtr; aˆk, bˆkw
>
i vjt)
)
1[0 ≤ w>i vjt ≤ 1] , (7)
where (mˆ, aˆ, bˆ)k are the weights derived from the empirical Bayes procedure.
The scale regression form of the inner product is due to the property that the
gamma random variable is being multiplied by the effect of the drug. That is,
the population of cells is being killed at some latent rate. The inner product
is constrained to be a proportion, as the drugs are known not to help any cells
grow (i.e., the proportion must be at most 1) and a drug cannot kill more than
all of the cells. The likelihood in eq. (7) is non-conjugate to the BTF hierarchical
model and thus we use the generalized elliptical slice sampling routine from
Section 3 for inference.
5 Results
We study BTF in two scenarios: (i) a dynamic matrix factorization with Poisson
observations and (ii) a real cancer drug study. In both cases, we run 5 independent
trials, holding out a different subset and report averages over all trials. BTF
outperforms all baselines in terms of log probability on held out data for both
benchmarks.
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Poisson Dynamical System
Observations True rate
Model NLL MAE RMSE
NMF 437.32± 31.73 1.46± 0.32 2.26± 0.57
PGDS 396.98± 11.86 1.24± 0.22 1.98± 0.40
BTF 369.91± 7.66 0.87± 0.18 1.24± 0.28
Cancer Drug Study
Observations
Model NLL
NMF 262.75± 308.12
LMF 589.17± 582.29
BTF −80.22± 9.67
Table 1: Mean results ± standard error on held out data in the benchmarks;
smaller is better for all metrics. NMF: nonnegative matrix factorization; PGDS:
Poisson-gamma dynamical system; LFM: logistic factor model; BTF: Bayesian
tensor filtering (this paper).
Non-stationary Poisson dynamical systems. We benchmark BTF on a
synthetic functional Poisson matrix dataset where the observations are Poisson
distributed with a latent rate curve for each function. The rate at every point in
the curve is the inner product of two gamma random vectors,
hj` ∼ Bern(0.2) , uj`d ∼ (1− hj`)δ0 + hj`Ga(1, 1) , vjtd =
t∑
`=1
uj`d ,
wid ∼ Ga(1, 1) , yijt ∼ Pois(〈wi, vjt〉) .
The resulting true rates form a monotonic curve of constant plateaus with
occasional jumps. As in the dose-response data, the columns evolve independently
of each other, rather than through a common time parameter. We set the latent
factor dimension to 3.
We compare BTF to nonnegative matrix factorization (NMF) and the Poisson-
gamma dynamical system (PGDS) model of Schein et al. [18]. We use the default
parameters for PGDS; for BTF, we set ρ2 = 0.1; both models use the true factor
dimension 3. We run both BTF and PGDS for 2000 burn-in iterations and collect
2000 samples on an 11 × 12 × 20 tensor with the upper left 3 × 3 × 20 corner
held out. We conduct 5 independent trials, regenerating new data each time
and evaluating the models on the held out data. We measure performance in
three metrics: mean absolute error (MAE) on the true rate, root mean squared
error (RMSE) on the true rate, and negative log-likelihood (NLL) on held out
observations. Table 1 (left) presents the results.
The PGDS model outperforms the NMF baseline, and BTF outperforms
both methods. There are two possible reasons for the better performance of
BTF relative to PGDS. First, the PGDS model uses a common “time” factor for
all columns, but in our simulation columns evolve independently. Second, the
large discrete jumps are not well-modeled by PGDS. In follow-up experiments,
we found no improvement for PGDS from using larger factor sizes to potentially
account for the first issue. This suggests the local adaptivity of BTF accounts
for the better performance.
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Cancer drug study. We evaluate our empirical Bayes dose-response model,
built on top of BTF, on a cancer drug study. The study tested 35 drugs against
28 tumor samples, each at 9 different concentrations. The standard dose-response
modeling approach in cancer datasets is a log-linear logistic model [25]. For a
baseline, we extend that model to a logistic factor model (LFM), using the same
preprocessing strategy; we also compare to NMF as a second baseline.
We run 5 independent trials, holding out 30 curves at random, subject to the
constraint that no column or row is left without any observations in the training
set. We choose the LFM factor size by 5-fold cross-validation on the training set.
For BTF, we perform a grid search over hyperparameters: ρ2 = {0.001, 0.01, 0.1},
factor size D = {1, 3, 5, 8}, and the order of the trend filtering matrix k = {0, 1};
we select the best model using the deviance information criterion [4].
Table 1 (right) present the results. BTF outperforms both baselines in terms
of NLL. Furthermore, the BTF procedure is also more stable, with a much lower
reconstruction variance than either baseline. This suggests BTF not only forms
a more accurate basis for a dose-response model, but is also more reliable.
6 Conclusion
We presented Bayesian Tensor Filtering, a hierarchical Bayesian model for
functional matrix factorization. BTF uses locally-adaptive shrinkage priors to
encourage smoothness in the functions while still allowing for sharp discontinuities.
We derived a Gibbs sampling inference procedure for BTF, including a new
slice sampling technique for constrained multivariate normal priors with non-
conjugate likelihoods. BTF was then used as the basis for a new dose-response
model for multi-drug, multi-sample studies. Finally, on both simulated and real
data benchmarks, the BTF-based models better reconstructed held out data in
comparison to state-of-the-art models.
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A Gaussian likelihood
When the likelihood is normal, yijt ∼ N (w>i vjt, ν2), where ν2 is a nuisance param-
eter, the factor and loading updates are conjugate. Let V˜ = (v1,1, v1,2, . . . , v1,T , v2,1, . . . , vM,T ),
and Ω−1 = diag{1/ν2}, then the updates are multivariate normal,
Q(i) = (V˜ TΩ−1V˜ + diag(σ−2))−1
(wi | −) ∼ MVN
(
Q(i)V˜ >Ω−1vec(Y >i ), Q
(i)
)
T (j) = diag(1/(ρ2τ2j ))
Σ(j) = (ID ⊗∆>T ∆) + (W ⊗ IT )>Ω−1(W ⊗ IT )
(vec(Vj) | −) ∼ MVN(Σ(j)(W ⊗ IT )Ω−1vec(Y >·j ),Σ(j)) ,
(8)
where diag diagonalizes the given vector, vec is the vectorization operator,
and ⊗ is the Kronecker product. In both the wi and Vj updates the precision
matrices will be sparse, making sampling from the conditionals computationally
tractable.
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B Binomial and related likelihoods via Pólya–Gamma
augmentation
When the likelihood is binomial, yijt ∼ Bin(nijt, 1/{1 + ew>i vjt}), where nijt is
a nuisance parameter, the updates are conditionally conjugate given a Pólya–
Gamma (PG) latent variable sample [17],
(ψijt | −) ∼ PG(nijt, w>i vjt) , (wi | −) ∼ N(mψi ,Σψi) , (9)
where Σψi = (V˜ >ΨiV˜+σ−2I)−1,mψi = Σψi V˜ >κ, Ψi = diag(ψ(i,1,1), . . . , ψ(i,M,T )),
and κ = (y(i,1,1) − n(i,1,1)/2, . . . , y(i,M,T ) − ni,M,T /2). The updates for V follow
analogously. PG augmentation can be applied to binomial, Bernoulli, negative
binomial, and multinomial likelihoods, among others.
16
C Local shrinkage updates
The local shrinkage parameters τj` can be updated through a double latent
variable augmentation trick,
(τj` | −) ∼ InvGamma(D + 1,
∣∣∣∣∣∣∆(k)Vj∣∣∣∣∣∣2
2
/2 + 1/cj`)
(cj` | −) ∼ InvGamma(1, 1/τ2j` + 1/φj`)
(φj` | −) ∼ InvGamma(1, 1/cj` + 1/ηj`)
(ηj` | −) ∼ InvGamma(1, 1/φj` + 1) .
(10)
The updates in eq. (10) come from the HS+ prior being a two-level horseshoe
prior. The inverse-gamma latent variable augmentation for the horseshoe is fast
and typically mixes quickly [13].
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